Phase 1 Study of Fisogatinib (BLU-554) in Patients (pts) with Advanced Hepatocellular Carcinoma (aHCC) Expressing FGF19: Preliminary Results from Chinese Pts in Part 3 of the Study

CS1001, an anti-PD-L1 antibody, combined with capecitabine and oxaliplatin (XELOX) as a first-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ): Updated efficacy, biomarker, and safety results

Safety and Efficacy Results from an Open-label, Multicentre, Phase I/II Study of Avapritinib in Chinese Patients with Gastrointestinal Stromal Tumor (GIST): A Bridging Study of NAVIGATOR

CS1001（抗PD-L1单抗）治疗复发或难治性结外自然杀伤细胞/T 细胞淋巴瘤患者: 一项评估其有效性和安全性的II期关键性临床试验更新结果

Updated Results from a Multicenter, Single-Arm, Phase 2 Study of CS1001, an Anti-Programmed Death-Ligand 1 (PD-L1) Human Monoclonal Antibody (mAb), in Patients (pts) with Relapsed or Refractory Extranodal Natural Killer/T Cell Lymphoma (R/R ENKTL)

一项Avapritinib治疗中国不可手术切除的或转移性胃肠道间质瘤（GIST）受试者的安全性、药代动力学（PK) 和有效性的开放性、多中心、Ⅰ/Ⅱ期研究

Safety, pharmacokinetics (PK) and efficacy results from an open-label, multicenter, Phase 1/2 study of avapritinib in Chinese patients (pts) with unresectable or metastatic gastrointestinal stromal tumors (GIST)

Preliminary safety, pharmacokinetics, and efficacy results from an open-label, multicenter, Phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors (GIST)